Decoding cinnabarinic acid specific stanniocalcin 2 induction by aryl hydrocarbon receptor

Nikhil Y. Patil¹, Hui Tang², Iulia Rus¹, Kangling Zhang², Aditya D. Joshi¹*

¹Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117
²Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555
Running Title: Agonist-specific differential gene regulation by liver AhR

Corresponding author: * Dr. Aditya D. Joshi, Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Ave., Oklahoma City, Oklahoma 73117, E-mail: aditya-joshi@ouhsc.edu

Number of Text Pages: 42
Number of Tables: 0
Number of Figures: 7 + 2 supplementary
Number of References: 67
Number of Words in the Abstract: 246
Number of Words in the Introduction: 481
Number of Words in the Discussion: 1334

Abbreviations: AhR, Aryl hydrocarbon receptor; Arnt, Aryl hydrocarbon receptor nuclear translocator; cyp1a1, cytochrome P450 family 1 member A1; stc2, stanniocalcin 2; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; CA, cinnabarinic acid; XREs, xenobiotic response elements; H3 K14ac, Histone H3 lysine 14 acetylation; H3 K23ac, Histone H3 lysine 23 acetylation; H3 K27dime, Histone H3 lysine 27 dimethylation; H4 K5ac, Histone H4 lysine 5 acetylation; H3 K79me, Histone H3 lysine 79 methylation.
Abstract

Aryl hydrocarbon Receptor (AhR) is a ligand mediated transcription factor known for regulating response to xenobiotics, including prototypical 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the activation of cytochrome P450 1A1 (encoded by cyp1a1) expression. Upon ligand-binding AhR translocate to nucleus, interacts with AhR nuclear translocator (Arnt) and bind to xenobiotic response element(s) (GCGTG, XREs) present in the promoter region of AhR regulated genes. Recently, we identified a novel tryptophan catabolite, cinnabaric acid (CA) as an endogenous AhR agonist capable of activating expression of AhR target gene, stanniocalcin 2 (stc2). The CA-driven stc2 induction bestowed cytoprotection against hepatotoxicity in an AhR-dependent manner. Interestingly, only CA, but not TCDD was able to induce stc2 expression in liver and CA was unable to upregulate the TCDD responsive cyp1a1 gene. In this report, we identified CA-specific histone H4 K5 acetylation and H3 K79 methylation at AhR-bound stc2 promoter. Moreover, histone H4 K5 acetylation writer, Atf2 and H3 K79 methylation writer, Dot1l were interacting with AhR-complex at stc2 promoter exclusively in response to CA treatment concurrent with the histone epigenetic marks. Suppressing Atf2 and Dot1l expression using RNA interference confirmed their role in stc2 expression. CRISPR/Cas9 assisted replacement of cyp1a1 promoter encompassing XREs with stc2 promoter XREs resulted in CA-dependent induction of cyp1a1 underlining fundamental role of quaternary structure of XRE sequence in agonist-specific gene regulation. In conclusion, CA-driven recruitment of specific chromatin regulators to AhR complex and resulting histone epigenetic modifications may serve as a molecular basis for agonist specific stc2 regulation by AhR.
Significance Statement

Results reported here provide a mechanistic explanation for the agonist-specific differential gene regulation by identifying interaction of AhR with specific chromatin regulators concomitant with unique histone epigenetic marks. This study also demonstrated that the agonist-specific target gene expression can be transferred with the gene-specific promoter XRE sequence in the context of chromatin architecture.
Introduction

The basic helix-loop-helix Per/Arnt/Sim domain family (bHLH-PAS) of transcription factors and regulators have distinct physiological, pathological and developmental functions despite conserved domain architecture (McIntosh et al., 2010). Within the family, the Aryl hydrocarbon Receptor (AhR) is a key transcription factor activated by number of xenobiotics including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Hankinson, 1993; Hankinson, 1995; Legraverend et al., 1982; Nebert and Gelboin, 1968a; Nebert and Gelboin, 1968b; Nebert et al., 1993). In an unliganded state, AhR resides in the cytoplasm in complex with molecular chaperonins – heat shock protein 90 (hsp90), p23, and AhR interaction protein (AIP) (Flaveny et al., 2010; Ma et al., 2009). Upon TCDD binding, AhR dissociates from chaperonins, translocate to the nucleus, and heterodimerizes with Aryl hydrocarbon Receptor nuclear translocator (Arnt) (Fukunaga et al., 1995). The liganded AhR-Arnt complex then binds to Xenobiotic Response Elements (XREs, GCGTG motif) present in the promoter region of AhR target genes, including archetypical cyp1a1 (Elferink et al., 1990; Elferink and Whitlock, 1990; Jones et al., 1986).

Since the discovery of AhR, wide range of xenobiotics including polycyclic aromatic hydrocarbons, halogenated aromatic hydrocarbons, polychlorinated biphenyls have been identified as exogenous AhR ligands (Nguyen and Bradfield, 2008). Additionally, recent advancement in the field included plethora of structurally diverse bacterial products, dietary and endogenous compounds as AhR agonists (Denison and Nagy, 2003; Denison et al., 2011; Hubbard et al., 2015). Among them, cinnabarinic acid (CA), a tryptophan metabolite and a byproduct of kynurenine pathway has been shown...
to activate AhR (Lowe et al., 2014). Upon CA treatment, AhR-Arnt complex is directly recruited to the 8 XREs clustered in 218 bp region of stanniocalcin 2 (stc2) promoter (Harper et al., 2013). Interestingly, in hepatocytes only CA but not TCDD, induced stc2 expression through an XRE-driven mechanism; whereas CA, in contrast to TCDD, did not upregulate cyp1a1 expression (Harper et al., 2013; Joshi et al., 2015). The CA-driven AhR-dependent stc2 upregulation was responsible for the protection against endoplasmic reticulum / oxidative stress – induced apoptosis both in vitro and in vivo (Joshi et al., 2015). To investigate the molecular basis for the agonist specific mutually exclusive transcription response, we previously employed mass spectrometry on immunoaffinity purified AhR complexes captured after CA or TCDD treatments (IP-MS) (Joshi et al., 2017). Mass spectrometry identified CA-specific interaction of AhR with metastasis-associated protein 2 (Mta2) – a known chromatin regulator, concomitant with histone H4 lysine 5 acetylation (H4 K5ac). Moreover, H4 K5ac was absolutely dependent on CA-induced AhR-Mta2 recruitment to the stc2 XREs and played critical role in the regulation of stc2 gene expression (Joshi et al., 2017). Current study extends from our previous observation and utilize cross-linking chromatin immunoprecipitation coupled mass spectrometry (xChIP-MS) to identify additional histone epigenetic marks namely, TCDD-specific H3 K14 acetylation, H3 K23 acetylation and H3 K27 dimethylation as well as CA-exclusive H3 K79 methylation at AhR-bound chromatin complex.

In the present study, we demonstrated transient binding of H4 lysine 5 acetylation and stable association of H3 lysine 79 methylation (H3 K79me) at the AhR-bound stc2 promoter in response to CA treatment. Moreover, H4 K5ac and H3 K79me
marks were concurrent with the interaction of histone modification writers Atf2 and Dot1l to the AhR-complex at the stc2 promoter resulting in target gene induction. Finally, this study has enhanced our understanding of AhR biology by exhibiting that the dynamic quaternary structure of the stc2 promoter containing XREs encodes comprehensive epigenetic and chromatin structural information necessary for the CA-specific AhR binding and AhR-mediated transcription of stc2.
Materials and Methods

Animals, cell culture and treatments. 8 to 10-week-old C57BL/6 (wild-type, WT) (Jackson Laboratories, Bar Harbor, ME) female mice were used in compliance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at the University of Oklahoma Health Sciences Center (OUHSC) and the University of Texas Medical Branch (UTMB). Mice were treated by oral gavage with vehicle (corn oil), 20 µg/kg 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (AccuStandard, New Haven, CT) or i.p. injection with 12 mg/kg cinnabarinic acid (CA) (synthesized by Synthetic Organic Chemistry Core at UTMB) for 0, 5, 10, 15, 30 min and 1, 2, 4, 6, 8, 12, 24 hr before sacrifice. For cell culture experiments, AML12 cell-line, a differentiated non-transformed mouse hepatic cells (ATCC, CRL-2254) were plated at a density of 500,000 cells/cm^2 in DMEM:F12 medium containing 10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, 40 ng/ml dexamethasone, penicillin (100 U/ml), streptomycin (100 µg/ml) and 5% fetal bovine serum (FBS). AML12 cells were transiently transfected with ON-TARGETplus Atf2 and Dot1l siRNAs (ThermoFisher Scientific, Waltham, MA) for 24 hr using Metafectene PRO (Biontex Laboratories, GmbH München, Germany) transfection agent. Cells were further treated with 6 nM TCDD, 30 µM CA or vehicle (DMSO) for 2 hr. In both cell culture and animal studies, treatment with vehicle, TCDD and CA were performed blindly to the experimenter by another individual.

Crosslinking chromatin immunoprecipitation coupled LC-targeted MS / MS (xChIP-MS). Upon TCDD or CA treatments, liver tissues from WT mice were extracted, finely minced, and subjected to two-step crosslinking chromatin immunoprecipitation (Tian et al., 2012). Briefly, minced livers were crosslinked using 2 mM disuccinimidyl
glutarate (DSG, 7.7 Å spacer arm) (ThermoFisher Scientific) in phosphate buffered saline for 45 min at room temperature. Further cross-linking with 1% formaldehyde (ThermoFisher Scientific) in phosphate buffered saline was carried out at room temperature for 10 min. Crosslinked samples were homogenized using Dounce homogenizer and centrifuged at 3200 x g for 5 min at 4°C. The supernatant was discarded and the pellet was resuspended in the cell lysis buffer (150 mM NaCl, 25 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X, 0.1% SDS, 0.5% deoxycholate, protease inhibitor cocktail), Dounce homogenized, incubated on ice for 20 min, centrifuged at 3200 x g for 5 min at 4°C, and the pellet was processed using ChIP-IT Express shearing Kit (Active Motif, Carlsbad, CA). Genomic DNA shearing was performed with adaptive focused acoustic sonicator (Covaris, Woburn, MA) to yield ~400 bp DNA fragments bound to protein complex. Immunoprecipitation was carried out by antibody targeting AhR (abcam, Cambridge, MA). Protein-DNA complexes were eluted using elution buffer provided in the kit. Proteins were extracted using SDS loading buffer containing 100 mM DTT followed by incubation at 100°C for 10 min. Proteins were separated using SDS-PAGE gel electrophoresis, stained with Coomassie blue, distained and bands cut out for subsequent mass spectrometry analysis. Gel bands were washed three times with 50% methanol and deionized water, dried by a piece of tissue paper and grinded into fine powder with a tip-sealed 200 µl pipette tip. 50 mM ammonium bicarbonate (100 µl) was added to cover the gel powder. Samples were digested overnight at 37°C by addition of 2 µg trypsin. Digested peptides were extracted by acetonitrile, dried by speedvac and then re-dissolve in 50 µl of 1% formic acid for LC-MS/MS analysis. Peptide mixtures were separated by reversed-phase liquid chromatography using an Easy-nanoLC
equipped with an autosampler (ThermoFisher Scientific). A PicoFrit 25 cm length × 75-µm id, ProteoPepTM analytical column packed with a mixed (1:1) packing material (Waters XSelect HSS T3, 5µ, and Waters YMC ODS-AQ, S-5, 100Å) was used to separate peptides by reversed-phase liquid chromatography (solvent A, 0.1% formic acid in water; solvent B, 0.1% formic acid in acetonitrile), running with a 176-min of gradient from 2 to 45% of solvent B with a flow rate at 300 µL/min. The QExactive mass analyzer (ThermoFisher Scientific GmbH, Bremen, Germany) was set to acquire data at a resolution of 35,000 in full scan mode and 17,500 in MS/MS mode. The top 15 most intense ions in each MS survey scan were automatically selected for MS/MS. Peptides were identified by PEAK® 8.5 (Bioinformatics Solutions, Waterloo, Canada) to perform De Novo sequencing assisted search against the mouse database (Searched Entry: 52485). Acetylation, mono-methylation, di-methylation, tri-methylation and citrullination of lysine were set as variable modifications. FDR were estimated by the ratio of decoy # hits over target # hits among PSMs. Maximum allowed -10logP is >=15.

**RNA isolation and quantitative RT-PCR.** Total RNA was isolated from vehicle, TCDD and CA treated mice livers and AML12 cells using Trizol (ThermoFisher Scientific). cDNA was prepared from 1 µg total RNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, California). Quantitative RT-PCR was performed using StepOnePlus real time PCR system (ThermoFisher Scientific) using cyp1a1 Forward 5' GCCTAACTCTTCCCTGGATGC 3’, cyp1a1 Reverse 5' TCAATGAGGCTGTCTGTGATGTC 3’, stc2 Forward 5' GTCGGTGTGATTGTGGAGATGAT, stc2 Reverse 5' TCCACATAGGGCTCATGCAG, 18s rRNA Forward 5' CTCAACACGGGAACCTCAG 3' and 18s rRNA reverse 5'
CGCTCCACCAACTAAGAACG 3’ primers and PowerUp SYBR Green Master Mix (ThermoFisher Scientific).

Chromatin Immunoprecipitation (ChIP). Following treatments with vehicle, TCDD and CA, liver tissues from WT mice were extracted, finely minced and fixed with 1% formaldehyde in phosphate buffered saline at room temperature for 10 min. Livers were homogenized using Dounce homogenizer, centrifuged at 3200 x g for 5 min at 4°C, and resuspended in 2 ml cell lysis buffer (150 mM NaCl, 25 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X, 0.1% SDS, 0.5% deoxycholate, protease inhibitor cocktail). Samples were incubated on ice for 15 min, centrifuged at 3200 x g for 5 min at 4°C and processed through ChIP-IT Express Enzymatic Kit (Active Motif) according to manufacturer’s instructions. AML12 cells were crosslinked with 1% formaldehyde and processed as per the manufacturer’s protocol (Active Motif). Antibodies against AhR, histone H3 (ab cam); histone H4, histone H4 K5ac, histone H3 K79me, IgG (Cell Signaling Technology, Danvers, MA); Atf2, Dot1l (Santacruz Biotechnology, Dallas) were used to immunoprecipitate protein bound DNA complexes. Immunoprecipitated and input DNA was PCR amplified using primers specific to the cyp1a1 and stc2 promoters flanking the XREs. The cyp1a1 and stc2 PCR primer pairs are cyp1a1 forward 5’-CTATCTCTTAAACCCACCCCCAA-3’, cyp1a1 reverse 5’-CTAAGTATGGGTGGAGGAAAGGGTG-3’ and stc2 forward 5’-CTCAGTCCATTCCGCCCATTGCCC-3’, stc2 reverse 5’-AGGAAGCGAGCGCCTCCGC-3’. For ChIP assays performed on the CRISPR/Cas9 edited AML12 cells cyp1a1 forward 5’ CAGGGGAGGGCAGGTGAAGG 3’ and cyp1a1 reverse 5’ TGGTGACTTTTGGCTTCCCTGG 3’ primers were used. PCR products were
fractionated on a 5% polyacrylamide gel, stained with SYBR Green (ThermoFischer Scientific) and imaged on a ChemiDoc MP imaging system (Bio-Rad).

**xChIP-Western blotting and Western blotting.** Two-step crosslinking chromatin immunoprecipitation (xChIP) using anti-AhR antibody was performed as described in the aforementioned xChIP-MS protocol. Upon crosslinking and chromatin immunoprecipitation using anti-AhR antibody, proteins were extracted with SDS loading buffer containing 100 mM DTT followed by incubation at 100°C for 10 min. Protein samples were fractionated by SDS-PAGE using Mini-Protean electrophoresis system (Bio-Rad) and transferred to 0.45 µm LF PVDF membranes (Bio-Rad) using Trans-blot turbo system (Bio-Rad). Membranes were probed with antibodies against histone H4, H4 K5ac, H3 K79me, H3 K14ac, H3 K23ac, H3 K27dime, p300, Cbp (Cell Signaling Technology); Atf2, Dot1l, Tip60, Mta2 (Santacruz Biotechnology); histone H3 (ab cam). For AML12 cells, extracts were prepared using cell lysis buffer (Cell Signaling Technology) and upon Western blotting were probed with anti-Atf2, anti-Dot1l (Santacruz Biotechnology), and anti-actin (Millipore Sigma, Sr Louis, MO) antibodies. Proteins were detected using IRDye 800CW and IRDye 680RD secondary antibodies (Li-COR, Lincoln, Nebraska) followed by imaging using an Odyssey CLx imaging system (Li-COR).

**Replacement of cyp1a1 promoter XREs with 'stc2 XRE cassette' in AML12 cells.** Using CRISPR-Cas9 editing, modified AML12 cell line was constructed by replacing 926 bp cyp1a1 promoter region (between -574 and -1500 from transcription start site) containing 10 XREs with 259 bp stc2 promoter region (- 210 to - 469) encompassing 8 XREs – ‘stc2 XRE cassette’ (Supp. Fig. 1A). Using Universal CRISPR activity assay
(Biocytogen, Wakefield, MA) TCTGGGCTCGGGAGCTCACA GGG as 5’ sgRNA and GGCACCCCATTGGCTTGTAGT AGG as 3’ guide sgRNA were chosen. Target vector construction, electroporation, and screening of positive clones was performed (Biocytogen). Junction PCR using HR allele primer pairs: CL-JGY-002-A-L-GT-F (TGTAAGGGTCGGGTGTCCTGAGAAT), Puromycin-GT-F (GCAACAGATGGAAGGCTCCTGGCG) and CL-JGY-002-A-R-GT-F (GCGGTCCTTCGGGCACCGTCGAC), CL-JGY-002-A-R-GT-R (TGGTGTTTCCAGTTCCCTGAAGCTC), non-HR allele primers CL-JGY-002-A-R-GT-F1 (GTTGTAAACTGTCCCCTGCATATC) and CL-JGY-002-A-R-GT-R (TGGTGTTTCCAGTTCCCTGAAGCTC) as well as DNA sequencing confirmed successful donor vector integration. A homozygous clone D02 was used in the present studies (referred to as CRISPR/Cas9 edited AML12 cells) (Supp. Fig. 1).

Statistical Analysis. xChIP-MS and xChIP-Western blotting assays to identify TCDD and CA-specific histone modifications and modifiers respectively were exploratory in nature. The xChIP-Western blotting (to confirm newly identified histone modifications), ChiP and qRT-PCR experiments were conducted with a preset plan. The sample sizes per group, blinding and data analysis methodology were predetermined (Michel et al., 2020). Data were analyzed by applying analysis of variance (ANOVA) models using Sigma Stat software (Systat Software, San Jose, CA). Differences between the groups were considered significant only if the p value is < 0.05.
Results

CA and TCDD induced differential gene expression of stc2 and cyp1a1. We have previously assessed mutually exclusive expression of AhR target genes, cyp1a1 and stc2 in response to 2 hr TCDD and CA treatments (Joshi et al., 2015; Joshi et al., 2017). Here, we measured cyp1a1 and stc2 mRNA message in the livers of TCDD (20 µg/kg) and CA (12 mg/kg) treated WT mice at different time points (Fig. 1). TCDD-driven induction of cyp1a1 was observed at 5 min and is plateaued at 1 hr (Fig. 1A). Maximal stc2 induction by CA was achieved at 24 hr with significant reduction in the message at 48 hr (Fig. 1B). Vehicle treatment did not elicit cyp1a1 or stc2 induction (Supp. Fig. 2A). The data confirmed that the agonist-specific dichotomous expression of cyp1a1 and stc2 persists temporally.

Identification of CA and TCDD specific histone post-translational modifications. To evaluate involvement of distinct epigenetic modifications in agonist-specific differential gene regulation, CA and TCDD-treated livers were crosslinked with protein-protein and protein-DNA crosslinkers and subjected to chromatin immunoprecipitation using anti-AhR antibody followed by mass spectrometry (xChIP-MS) (Sowers et al., 2015; Tian et al., 2012). xChIP-MS identified TCDD-specific histone H3 lysine 14 acetylation (H3 K14ac), lysine 23 acetylation (H3 K23ac), lysine 27 dimethylation (H3 K27dime) and CA-specific stable H3 K79 methylation (H3 K79me) marks at the AhR-bound chromatin complex (Fig. 2A and B). Moreover, we have previously confirmed association of H4 K5 acetylation (H4 K5ac) at AhR-bound stc2 promoter after CA but not upon TCDD or vehicle treatments (Fig. 2A) (Joshi et al., 2017). To verify interaction of specific epigenetic marks within AhR-bound chromatin, Western blotting on
crosslinked chromatin immunoaffinity purified AhR complexes (xChIP-WB) was performed. TCDD-specific association of AhR-complex with H3 K14ac at 48 hr; H3 K23ac at 4, 6, 8, 12 and 48 hr; and H3 K27dime between 2 to 48 hr was validated (Fig. 3). Histone H3 K14ac, K23ac and K27dime marks were not observed at AhR-bound chromatin upon CA or vehicle treatments (Fig. 3 and Supp. Fig. 2B). CA-specific AhR-bound H4 K5ac expression was transient between 2 to 24 hr – contemporaneous with CA-induced stc2 expression (Fig. 3). xChIP-immunoblotting also confirmed stable interaction of H3 K79me with CA-induced AhR complex (Fig. 3).

**Chromatin regulators associated with AhR-bound chromatin complex.** Given that the histone post-translational modifications are vital for regulating chromatin architecture and dynamic homeostasis of these modifications are driven by the recruitment of chromatin regulators such as ‘writers’ of histone modifications (Gillette and Hill, 2015), we sought to identify AhR-bound regulators of CA-specific histone modifications. We focused on specific histone modification ‘writers’ that are known or are likely to trigger H4 K5 acetylation and H3 K79 methylation (Hyun et al., 2017; Marmorstein and Zhou, 2014; Sandoval et al., 2016). xChIP-Western blotting revealed CA-specific interaction of known H4 K5 acetylation writer – activating transcription factor 2 (Atf2) with AhR-chromatin complex between 2 and 24 hr, concurrent with H4 K5 acetylation and stc2 induction (Fig. 4 and Supp. Fig. 2C). We were able to recapitulate previously detected association of histone reader, Mta2 with AhR uniquely in response to CA treatment (Joshi et al., 2017). Furthermore, CA-treatment resulted in an interaction of AhR-bound chromatin complex with a known H3 K79 methylation writer, disruptor of telomeric silencing 1-like histone lysine methyltransferase (Dot1l) (Fig. 4). Other lysine
acetyltransferases examined including p300, Cbp and Tip60 were associated with AhR-chromatin complex in response to both TCDD and CA treatments but not upon administration of the vehicle (Fig. 4 and Supp. Fig 2C).

**CA-specific direct recruitment of chromatin modification writers to stc2 promoter in vivo.** The 218 bp region of stc2 promoter between -244 and -462 bp upstream of transcription start site contain 8 distinct XREs (Harper et al., 2013). Prior studies have demonstrated recruitment of AhR-Arnt-Mta2 complex to stc2 promoter sequence in response to CA treatment (Joshi et al., 2015; Joshi et al., 2017). Here, we examined whether histone H4 K5 acetylation and H3 K79 methylation writers, Atf2 and Dot1l were recruited to the stc2 promoter encompassing the XRE cluster. Chromatin immunoprecipitation assay was performed on whole-liver tissue targeting XREs within stc2 and cyp1a1 promoter regions. CA-specific recruitment of Atf2 to stc2 promoter was observed between 2 and 24 hr, concurrent with the AhR binding (Fig. 5), H4 K5 acetylation (Fig. 3) and elevated stc2 expression (Fig. 1). Dot1l was stably bound to the stc2 promoter upon CA treatment (Fig. 5). Neither Atf2 and Dot1l were recruited to the cyp1a1 promoter upon CA treatment nor to the stc2 and cyp1a1 XREs upon TCDD or vehicle administration (Fig. 5 and Supp. Fig. 2D). Finally, AhR was bound directly to the cyp1a1 promoter upon TCDD treatment inducing cyp1a1 expression (Fig. 5).

**Histone writers Atf2 and Dot1l are essential for CA-driven stc2 expression.** AML12 cells were transiently transfected with Atf2, Dot1l and Non-Targeting (scrambled) siRNA oligonucleotides. Western blotting confirmed successful knock-down of Atf2 and Dot1l protein expression with RNA interference (Fig. 6A). Quantitative RT-PCR indicated that the loss of Atf2 and Dot1l significantly attenuated CA-induced stc2
expression whereas the cyp1a1 message remained unaltered (Fig. 6B). ChIP studies revealed that silencing Atf2 obliterated AhR recruitment to stc2 promoter and impeded H4 K5 acetylation (Fig. 6C). Similarly, suppressing Dot1l expression resulted in the loss of AhR and H4 K79me interaction at stc2 promoter. Silencing histone modification writers had no effect on TCDD-driven AhR binding to cyp1a1 promoter (Fig. 6C). Collectively, our data suggests that the CA-driven recruitment of chromatin regulators, Atf2 and Dot1l to AhR-chromatin complex triggers histone epigenetic modifications, including histone H4 K5 acetylation and H3 K79 methylation exclusively at stc2 promoter plausibly resulting in changes in chromatin structure thereby inducing stc2 expression.

Role of quaternary XRE structure in agonist-specific differential gene regulation.

We examined whether the quaternary structure of the stc2 promoter encompasses complete epigenetic and structural information necessary for the agonist specific recruitment of chromatin regulators, histone modifications and AhR-mediated regulation of stc2. A modified AML12 cell line was constructed by replacing 926 bp cyp1a1 promoter region containing 10 XREs (between -574 and -1500 bp from transcription start site) with stc2 promoter containing 8 XREs (between -210 to -469 bp from transcription start site, termed ‘stc2 XRE cassette’) using CRISPR/Cas9 editing (Fig. 7A). In the CRISPR/Cas9 edited AML12 cells, quantitative RT-PCR indicated upregulation of cyp1a1 gene expression in response to CA treatment (Fig. 7B). A marked reduction in cyp1a1 message upon TCDD treatment in edited cells was attributed to the lack of 10 XREs within cyp1a1 promoter (Fig. 7B). ChIP studies performed in WT AML12 cells displayed direct binding of AhR to cyp1a1 promoter upon
TCDD treatment (Fig. 7C). In CRISPR/Cas9 edited AML12 cells – AhR, Atf2 and Dot1l binding as well as interaction of H4 K5 acetylation and H3 K79 methylation to ‘stc2 XRE cassette’ within cyp1a1 promoter was observed exclusively in response to CA treatment (Fig. 7C). These results strongly suggest that the agonist-specific AhR-mediated stc2 expression can be transferred with the stc2 promoter sequence in the context of chromatin architecture. Finally, this study confirmed that the quaternary DNA structure contain comprehensive epigenetic and higher-order chromatin conformational information necessary to elucidate agonist-specific differential gene regulation by AhR.
Discussion

Since its discovery in 1976, Aryl hydrocarbon receptor has been a pivotal transcription factor in both environmental toxicology and molecular pharmacology (Poland et al., 1976a; Poland et al., 1976b). Apart from the identification of prototypical AhR ligands of anthropic origin, over the last 40 years number of natural structurally diverse AhR ligands with varying binding affinities have been discovered (Denison and Nagy, 2003; Denison et al., 2011). Moreover, a recent identification of the endogenous AhR agonist, CA presents a unique opportunity to study molecular mechanism underlying the CA and TCDD specific mutually exclusive regulation of stc2 and cyp1a1 genes by AhR (Harper et al., 2013; Joshi et al., 2015; Lowe et al., 2014). Our previous studies using electrophoretic mobility shift assays (EMSA) showed AhR binding to radiolabeled oligonucleotide probes encompassing individual cyp1a1 and stc2 promoter XREs in response to both TCDD and CA treatments (Joshi et al., 2017). This observation suggested that the agonist-specific AhR-mediated differential transcription regulation was ‘at least in part’ dependent on the tertiary chromatin structure plausibly due to the distinct cofactor binding and specific epigenetic modifications. Very few studies have reported evidence of ligand-specific cofactor recruitment by AhR. In mammalian cell culture systems, ligand-selective interaction of AhR with several cofactors including SRC1, SRC2, STC3, TRAP220, CARM1, and PGC1 was observed using two-hybrid assays (Zhang et al., 2008). Moreover, AhR agonists β-naphthoflavone and 3,3'-diindolylmethane (DIM) displayed differential cofactor recruitment to the cyp1a1 promoter in MCF7 cells (Hestermann and Brown, 2003). Agonist-specific cofactor binding was also observed in other nuclear receptors including glucocorticoid receptor...
(Monczor et al., 2019), androgen receptor (Muller et al., 2000), and epidermal growth factor receptor (ErbB/HER) (Saeki et al., 2009). However, the findings presented here are unique as our results indicate CA-specific recruitment of distinct histone modification writers (Atf2 and Dot1l) to AhR-chromatin complex, resulting in specific epigenetic modifications (H4 K5ac, H3 K79me) at stc2 promoter in vivo, responsible for regulating transcription of stc2.

Gene transcription is a highly orchestrated process tightly regulated by the local chromatin conformation (Chen and Li, 2010; Woodcock and Ghosh, 2010). The basic unit of chromatin, the nucleosome core contains two copies of four types of histones (H2A, H2B, H3 and H4) that can be post-translationally altered into at least 80 known covalent modifications (Zhao and Garcia, 2015). These histone modifications produce ‘histone code’ that influence nucleosome compactness and chromatin organization resulting in activation or silencing of transcription (Bannister and Kouzarides, 2011; Bartke and Kouzarides, 2011; Kouzarides, 2007). Our previous mass spectrometry analysis performed on the liver nuclei isolated from TCDD and CA treated mice identified CA-specific H4 K5 acetylation (Joshi et al., 2017). Further studies confirmed that the H4 K5ac at the stc2 promoter was concomitant with the interaction of Mta2 – a known chromatin modification ‘reader’ – with the AhR (Joshi et al., 2017). In order to catalog CA and TCDD specific histone modifications associated with AhR-bound chromatin temporally, we performed crosslinking chromatin immunoprecipitation coupled to LC-MS/MS (xChIP-MS) (Sowers et al., 2015; Tang et al., 2016; Tian et al., 2012). A parallel reaction monitoring, an ion monitoring technique based on high-resolution high-precision mass spectrometry was employed to simultaneously detect
multiple histone modifications. Parallel reaction monitoring has a broad dynamic range, measures all transitions, and is more resistant to background noise than conventional selective reaction monitoring (Tang et al., 2014). xChIP-MS identified a myriad of AhR-bound stable and transient histone acetylations and methylations across genome, albeit we focused on CA and TCDD specific mutually exclusive modifications. Histone H3 K14 acetylation, H3 K23 acetylation and H3 K27 dimethylation were uniquely observed at AhR-bound chromatin in response to TCDD treatment. Whereas, CA triggered stable association of H3 K79 methylation at AhR-chromatin complex (Fig. 2). Surprisingly, we did not detect H4 K5 acetylation with high confidence possibly due to the limitation of signal detection by MS, low abundance or loss during sample preparation (Bensaddek and Lamond, 2016). Nevertheless, xChIP-Western blotting successfully confirmed presence of H4 K5ac at AhR-bound chromatin exclusively upon CA treatment (Fig. 3).

Modifications on histone H4, specifically lysine residues in N-terminal tail (K5, 8, 12 and 16), are known to be involved in gene regulation and maintaining genome integrity (Shahbazian and Grunstein, 2007; Turner et al., 1989; Zheng et al., 2013). H4 K5 has largely been implicated in epigenetic priming (Park et al., 2013), bookmarking (Zhao et al., 2011) as well as transcription regulation (Borsos et al., 2015). Histone acetylation is controlled by families of non-redundant lysine acetyltransferase (KATs), which use acetyl CoA to form ε-N-acetyllysine on lysine residues of histone tails, neutralizes the positive charge on histone lysines, decreases the DNA-histone interaction, opens the chromatin structure, and facilitates recruitment of RNA polymerase II resulting in transcription activation of target genes (Bartke and Kouzarides, 2011). Previous studies have identified and characterized Tip60, Hbo1
Myst2), Cbp, p300, and Atf2 as known H4 K5 acetylation writers (Legube and Trouche, 2003). Moreover, several chromatin regulators are known to interact with AhR, including p300, Cbp, Src1, Tif2, p/CIP (Beischlag et al., 2002; Kobayashi et al., 1997). In this study, we reiterated interaction of histone acetylation ‘writers’ – p300, Cbp and Tip60 to AhR irrespective of agonist specificity (Fig. 4). On the contrary, Atf2 was associated with AhR-stc2 promoter complex exclusively in response to CA treatment. Atf2 is a member of the ATF/cAMP response element binding (CREB) protein family of basic region leucine zipper proteins and a bona-fide candidate reported to possess intrinsic lysine acetyltransferase activity (Nomura et al., 1993; Sheikh and Akhtar, 2019). Atf2 is known to interact with other transcription factors as well as bind to response elements on target genes and stimulate distinct transcription programs. Association of Atf2 with AP1 is known to alter local DNA structure and initiate transcription, Atf2-Jun interaction mediate transcription of IFNβ, and Atf2 binding to βHLH-PAS family member – HIF1α promotes its transcription activity (Choi et al., 2009; Falvo et al., 2000; Falvo et al., 1995). Therefore, it is conceivable that CA-specific interaction of Atf2 with AhR can directly or by recruitment of additional lysine acetyltransferases acetylate histone H4 K5. The acetylated mark is then accessed by chromatin modification readers such as previously identified Mta2 (Joshi et al., 2017; Wu, 2013) and/or Brd4 which employs the bromodomain to target the modified histone and regulate transcription (Shi and Vakoc, 2014).

This study also identified CA-specific stable association of H3 K79methylation at the AhR-chromatin complex (Fig. 2 and 3). Histone H3 K4methylation, K36methylation, and K79methylation are the three histone H3 methylation marks known to be associated
with an active form of chromatin (Hyun et al., 2017). ChIP-Chip arrays using H3 K79 methylation antibodies have revealed positive correlation of gene expression in mammalian cells with the recruitment of histone methyltransferase, Dot1l (Steger et al., 2008). Therefore, it is plausible that the CA-driven AhR-mediated recruitment of histone modification ‘writers’ – Atf2 and Dot1l confer specific epigenetic marks including H4 K5ac and H3 K79me, remodel the chromatin structure and provide access to the transcription machinery at the stc2 promoter. It is noteworthy, that AhR and Atf2 recruitment to the stc2 promoter and H4 K5 acetylation correlates with the kinetics of the stc2 induction. However, binding of Dot1l and H3 K79 methylation occurs as early as 5 minutes post CA treatment (Fig. 1 to 5). Previous studies have noted kinetic discrepancies between binding of AhR, p300, Src1, Tif2, p/CIP to the cyp1a1 promoter and cyp1a1 gene expression in response to different ligands (Hestermann and Brown, 2003). It is therefore feasible that additional transcription factors, coregulators and signaling pathways including pRb, E2F, RelA, NF-κB, estrogen receptor, Nrf2/Maf might cross-talk with CA and/or CA-bound AhR and thereby influence stc2 regulation (Denison et al., 2011; Jackson et al., 2014). Further chromatin proteomic profiling (David et al., 2017) as well as ChIP-seq studies are warranted to address differences in the kinetics and its impact on the agonist specific AhR-mediated gene regulation.

A modified AML12 cell line was constructed by replacing known dioxin-responsive elements within cyp1a1 promoter with the stc2 cassette containing 8 XREs (Lusska et al., 1993; Shen et al., 1991). In the CRISPR/Cas9 edited AML12 cells, histone epigenetic modifications (H4 K5ac, H3 K79me) and chromatin modification ‘writers’ (Atf2, Dot1l) were transferred in conjunction with the quaternary structure of the
stc2 promoter XREs resulting in a CA-dependent regulation of cyp1a1 expression. This reinforced the notion that the agonist-specific gene regulation by AhR is highly dependent on the ligand-specific cofactor recruitment and exclusive epigenetic signatures that influence chromatin architecture (Wajda et al., 2020). The diminished but persistent induction of cyp1a1 by TCDD in the edited cells is attributed to the functional XREs located beyond -1500 bp from transcription start site as acknowledged in the ChIP-seq studies (Fig. 7) (Nault et al., 2016). Our future studies beyond the scope of this manuscript will reveal genome-wide chromatin accessibility and nucleosome occupancy in response to CA versus TCDD treatments, determine presence of the CA-specific epigenetic signatures at other AhR-target genes, identify molecular interactions of AhR with the ‘readers’ and ‘erasers’ of histone modifications, and will ultimately probe into the mechanics of chromatin remodeling in response to the AhR agonists. Collectively, these observations strongly demonstrate that the distinct cofactor binding and epigenetic modifications play critical role in the agonist specific AhR mediated gene expression and highlights the complexities involved in the transcription regulation by AhR.
Acknowledgements

We thank Dr. Cornelis Elferink (University of Texas Medical Branch, Galveston) for the helpful discussions regarding xChIP-MS data analysis and CRISPR/Cas9 studies.
Authorship Contributions

Participated in research design: Joshi

Conducted experiments: Patil, Tang, Rus, Joshi

Contributed new reagent or analytical tools: Patil, Tang, Rus, Zhang, Joshi

Performed data analysis: Patil, Tang, Zhang, Joshi

Wrote or contributed to the writing of the manuscript: Patil, Tang, Zhang, Joshi
References


Hankinson O (1993) Research on the aryl hydrocarbon (dioxin) receptor is primed to take off. Archives of biochemistry and biophysics 300(1): 1-5.


Poland A, Glover E and Kende AS (1976b) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. The Journal of biological chemistry 251(16): 4936-4946.


Footnotes

This work was supported by the National Institutes of Diabetes and Digestive and Kidney Diseases grant R01DK122028; and Presbyterian Health Foundation – Harold Hamm Diabetes Center Seed Grant (to A. D. J.). Authors report no conflict of interest.
Figure Legends

**Figure 1.** Agonist specific dichotomous expression of stc2 and cyp1a1. WT mice were treated with 20 µg/kg of TCDD and 12 mg/kg of CA for the indicated time. RT-PCR was performed to quantitate (A) cyp1a1 and (B) stc2 mRNA levels in liver, normalized against 18s ribosomal RNA. For statistical analysis, a mixed-effects multivariate ANOVA (MANOVA) model was used. Following significant overall F test from MANOVA model, the posthoc multiple comparison tests were performed for the prespecified comparisons adjusted by Tukey procedure *p < 0.05, n = 3 independent mice.

**Figure 2.** Identification of CA and TCDD specific AhR-associated epigenetic modifications. WT mice were gavaged with 20 µg/kg of TCDD or i.p. with 12 mg/kg of CA for the denoted time period. Cross-linking chromatin immunoprecipitation was performed on livers using anti-AhR antibody followed by LC-MS/MS (xChIP-MS). (A) summarizes mutually exclusive histone modifications detected (denoted by D) upon TCDD and CA treatments at various time-points. * denotes H4 K5 acetylation previously detected by mass spectrometry and western blotting following 2 and 24-hour CA treatment. (B) Representative high-resolution MS/MS spectra of STGG^{14}K_{ac}APR (encompassing residues 10–17), QLAT^{23}K_{ac}AAR (residues 19–26), ^{27}K_{me2}SAPATGGVK (residues 27–36) and EIAQDF^{79}K_{me}TDLR (encompassing residues 73–83) in histone H3. For CA-specific H4 K5 acetylation, high resolution spectra of G^{5}K_{ac}GGKGLGKGGAKR (encompassing residues 4 – 17 in histone H4) with detailed information regarding theoretical and observed m/z values for fragment ions was published previously (Joshi et al., 2017).
**Figure 3.** Histone H4 K5 acetylation and H3 K79 methylation at AhR-chromatin complex exclusively upon CA treatment. Cross-linked chromatin immunoprecipitated (with anti-AhR antibodies) protein extracts were subjected to Western blotting and probed with anti-histone modification antibodies. One representative blot is shown (n = 3 independent mice). Histone H3 and H4 were used as loading controls. 0, 5, 10, 15, 30 indicate time in minutes and 1, 2, 4, 6, 8, 12, 24, 48 are hours of 20 µg/kg of TCDD and 12 mg/kg of CA treatment.

**Figure 4.** Identification of AhR-associated chromatin modification writers of H4 K5 acetylation and H3 K79 methylation. Livers of TCDD and CA treated WT mice were chromatin immunoprecipitated with anti-AhR antibody as described in Materials and Methods. Immunoblotting was carried out to detect enrichment of known histone modification writers of H4 K5 acetylation and H3 K79 methylation. Western blots shown are representative results from 3 independent experiments. 0, 5, 10, 15, 30 indicate time in minutes and 1, 2, 4, 6, 8, 12, 24, 48 are hours of 20 µg/kg of TCDD and 12 mg/kg of CA treatment.

**Figure 5.** CA-dependent Atf2 and Dot1l binding to stc2 promoter *in vivo*. Chromatin immunoprecipitation (ChIP) assays were performed on livers from WT mice treated with TCDD (20 µg/kg) and CA (12 mg/kg) for 0, 5, 10, 15, 30 minutes and 1, 2, 4, 6, 8, 12, 24, 48 hours. Antibodies against the histone modification writers Atf2, Dot1l and against AhR were used to immunoprecipitate the target proteins. Anti-IgG and anti-H3 antibodies were used as negative and positive controls respectively. PCR using primers
targeting XRE clusters in the stc2 and cyp1a1 promoters were used to amplify the precipitated DNA. PCR products were separated on two 5% polyacrylamide gels and visualized with SYBR Green dye. Samples were ran, stained with SYBR Green and imaged on Chemidoc MP (Bio-Rad) simultaneously with exactly same acquisition parameters. Representative images from the ChIP gels are shown. Quantitation of PCR products was performed using ImageLab software (Bio-rad). The bound fraction values were calculated as a percentage of the input DNA used in the immunoprecipitation representing 100% and is shown as mean of %bound from three independent experiments.

**Figure 6.** Atf2 and Dot1l are required for the transcription regulation of stc2. (A) AML12 cells were transiently transfected with Atf2 and Dot1l siRNAs or Non-Targeting siRNA (NT siRNA). Twenty-four hours later, Western blotting on cell lysates was performed to monitor both Atf2 and Dot1l protein expression. Actin was used as a loading control. (B) AML12 cells, transiently transfected with Atf2, Dot1l and Non-Targeting siRNA for 24 hours were treated with vehicle (DMSO), 6 nM TCDD and 30 µM CA for 2 hr. Quantitative RT-PCR was performed to measure cyp1a1 and stc2 mRNA normalized to 18s rRNA. For statistical analysis, a mixed-effects multivariate ANOVA (MANOVA) model was used. Following overall significant F test from MANOVA model, the posthoc multiple comparison tests were performed for the prespecified comparisons adjusted by Tukey procedure. *p < 0.05, n = 3 independent batches of AML12 cells. (C). ChIP assays were performed on AML12 cells transiently transfected with targeted and Non-targeted siRNA (NT siRNA) and treated with vehicle, TCDD and CA. PCR products
were loaded onto two 5% polyacrylamide gels (represented by space), ran, stained with SYBR Green and imaged on Chemidoc MP imager (Bio-Rad) simultaneously with exactly identical acquisition parameters. \( n = 3 \) for stc2 and 2 for cyp1a1.

**Figure 7.** Agonist-specific AhR target gene expression transfers with the gene-specific ‘XRE cassette’ in the context of chromatin architecture. An edited AML12 cell line was constructed by replacing 926 bp cyp1a1 promoter region containing 10 XREs (between -574 and -1500 bp from transcription start site) with stc2 promoter containing 8 XREs (259 bp region termed ‘stc2 XRE cassette’ – between -210 to -469 bp from transcription start site) using CRISPR/Cas9 technology. (A) Illustration of cyp1a1 and stc2 promoter regions. Red and blue rectangles represent XREs (5’-GCGTG-3’) within cyp1a1 and stc2 promoters respectively. CRISPR/Cas9 edited AML12 cells, where 259 bp stc2 XRE cassette is inserted by replacing cyp1a1 XREs within -574 and -1500 bp is depicted. (B) WT (black bars) and CRISPR/Cas9 edited (grey bars) AML12 cells were treated with vehicle (DMSO), 6 nM TCDD and 30 µM CA for 2 hr. Quantitative RT-PCR was performed to measure RNA expression of cyp1a1 and stc2 and normalized to 18s rRNA. For statistical analysis, a mixed-effects multivariate ANOVA (MANOVA) model was used. Following overall significant F test from MANOVA model, the posthoc multiple comparison tests were performed by Tukey procedure. *p < 0.05, \( n = 3 \) independent batches of AML12 cells. (C) Vehicle, TCDD and CA treated, WT and edited AML12 cells were subjected to chromatin immunoprecipitation using antibodies against AhR, H4 K5ac, Atf2, H3 K79me, Dot1l and H3 (positive control). PCR products were fractionated and visualized on 5% polyacrylamide gels stained with SYBR Green.
Samples were ran on separate gels (represented by space), stained with SYBR Green and imaged on Chemidoc MP imager (Bio-Rad) synchronously with exactly same acquisition parameters (n = 3 independent batches of AML12 cells).
Figure 1

A

B

<table>
<thead>
<tr>
<th>Time</th>
<th>0 min</th>
<th>5 min</th>
<th>10 min</th>
<th>15 min</th>
<th>30 min</th>
<th>1 hr</th>
<th>2 hr</th>
<th>4 hr</th>
<th>6 hr</th>
<th>8 hr</th>
<th>12 hr</th>
<th>24 hr</th>
<th>48 hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>copi1 mRNA (fold change)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>str2 mRNA (fold change)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTM</td>
<td>TIME</td>
<td>0 min</td>
<td>5 min</td>
<td>10 min</td>
<td>15 min</td>
<td>30 min</td>
<td>1 hr</td>
<td>2 hr</td>
<td>4 hr</td>
<td>6 hr</td>
<td>8 hr</td>
<td>12 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>----------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>H3 K14 acetylation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>-</td>
</tr>
<tr>
<td>H3 K23 acetylation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>H3 K27 dimethylation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>-</td>
<td>D</td>
<td>-</td>
</tr>
<tr>
<td>H4 K5 acetylation*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>D</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3 K79 methylation</td>
<td>-</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>-</td>
<td>D</td>
<td>-</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
</tbody>
</table>

**Cinnabarinic acid**

**TCDD**

**H3 - STGSGKAPR**

Calculated [M+2H]^2+: 408.2221
Measured [M+2H]^2+: 408.224 (3.1 ppm)

**Cinnabarinic Acid**

**TCDD**

**H3 - EIADFDFKVDGL**

Calculated [M+3H]^3+: 450.5376
Measured [M+3H]^3+: 450.5376 (0.2 ppm)
Figure 5
Figure 6